UTHR

United Therapeutics Corp

553.88

Oct 20 • 3:59 PM ET +10.73 (1.98%)

559.12

Aftermarket • 7:30 PM ET +5.24 (0.95%)

Healthcare Drug Manufacturers - Specialty & Generic USA Large NASD

Oct 20, 7:23 AMUnited Therapeutics announces the opening of its third designated pathogen-free xenograft production facility, expanding the company’s organ manufacturing capabilities.

Peers: LQDA INSM MRK NBIX ALKS JNJ MNKD JAZZ GOSS BMRN

| Held by: IJH VTI VB VXF MDY IBB VBR XBI XMHQ XMMO

Scroll to Statements

Index	-
Market Cap	23.76B
Enterprise Value	21.09B
Income	1.31B
Sales	3.15B
Book/sh	149.97
Cash/sh	62.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1400
IPO	Jun 17, 1999

P/E	19.81
Forward P/E	17.47
PEG	1.87
P/S	7.53
P/B	3.69
P/C	8.92
P/FCF	21.80
EV/EBITDA	14.11
EV/Sales	6.69
Quick Ratio	5.41
Current Ratio	5.73
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	27.96
EPS next Y	31.71
EPS next Q	6.03
EPS this Y	-4.41%
EPS next Y	19.07%
EPS next 5Y	9.33%
EPS past 3/5Y	22.94% 19.27%
Sales past 3/5Y	18.02% 16.50%
EPS Y/Y TTM	9.29%
Sales Y/Y TTM	2.49%
EPS Q/Q	13.46%
Sales Q/Q	-1.92%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	5.95% -2.65%

Insider Own	3.31%
Insider Trans	-51.17%
Inst Own	97.69%
Inst Trans	-1.43%
ROA	17.33%
ROE	19.32%
ROIC	20.48%
Gross Margin	86.14%
Oper. Margin	44.49%
Profit Margin	41.56%
SMA20	4.81%
SMA50	7.50%
SMA200	4.99%
Trades

Shs Outstand	42.68M
Shs Float	41.47M
Short Float	8.67%
Short Ratio	5.15
Short Interest	3.60M
52W High	609.35 -9.10%
52W Low	409.07 35.40%
Volatility	3.86% 4.07%
ATR (14)	19.67
RSI (14)	60.20
Beta	0.50
Rel Volume	0.64
Avg Volume	698.37K
Volume	443,554

Perf Week	1.93%
Perf Month	12.33%
Perf Quarter	5.09%
Perf Half Y	-3.41%
Perf YTD	13.67%
Perf Year	28.01%
Perf 3Y	145.70%
Perf 5Y	188.07%
Perf 10Y	389.99%
Recom	1.53
Target Price	662.07
Prev Close	543.15
Price	553.88
Change %	1.98%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-26	Upgrade	BTIG Research	Neutral → Buy	$728
Sep-24-26	Initiated	Goldman	Sell	$321
May-07-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$735
Apr-10-26	Initiated	Raymond James	Outperform	$700
Oct-20-25	Initiated	Wells Fargo	Underweight	$414
Sep-26-25	Initiated	RBC Capital Mkts	Outperform	$569
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight	$405
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205

Show Previous Ratings

Oct-20-26 07:00AM	United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility (Business Wire)
Oct-19-26 07:00AM	United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD (Business Wire)
Oct-16-26 05:26AM	Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure (Stocktwits)
Oct-14-26 09:47PM	How Much Downside Is Left In Liquidia Stock? (Trefis)
12:07PM	Liquidia shares surge 25% as settlement ends United Therapeutics litigation (Proactive)
10:24AM	Loading…
10:24AM	?? Under the Radar: Liquidia Stock Soars After Settling Patent Fight (The Wall Street Journal)
10:15AM	LQDA Stock Rockets 40% Today BTIG Calls United Therapeutics Settlement Better Than Best-Case Scenario (Stocktwits)
05:13AM	Liquidia shares surge to 5-month high premarket on United Therapeutics settlement (Investing.com)
Oct-13-26 07:39PM	LQDA Explodes After Hours On Deal Ending Years Of Patent Fight, Keeping YUTREPIA On Market (Stocktwits)
06:26PM	Liquidia stock surges 40% on $380.7M litigation settlement with UTHR (Investing.com)
07:00AM	United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting (Business Wire)
Oct-02-26 06:40AM	Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb Liquidia And FICO Face Downgrades (Stocktwits) -5.19%
Oct-01-26 02:07PM	LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path (Stocktwits) +5.44%
10:14AM	Liquidia Sinks Another 17% as BofA Cuts Target to $40 From $92 After Court Loss (TIKR)
09:38AM	Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls (The Fly)
01:03AM	Loading…
01:03AM	Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling. An Appeal Could Decide Whether Shares Rebound. (TIKR)
Sep-30-26 09:41PM	United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent (TIKR) +12.55%
07:09PM	United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia (Business Wire)
03:46PM	LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims (Stocktwits)
02:23PM	Liquidia shares crater after court rules for United Therapeutics (Investing.com)
Sep-24-26 09:41AM	CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls (The Fly)
Sep-18-26 11:46AM	Biotech Options Buzz: UTHR, NMRA, EWTX (Schaeffer's Research)
Sep-08-26 07:00AM	United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization (Business Wire)
Sep-02-26 07:00AM	United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso to Treat Idiopathic Pulmonary Fibrosis (Business Wire)
Sep-01-26 11:59PM	Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M (New Hampshire Union Leader, Manchester)
04:39PM	Top Research Reports for Toyota Motor, CrowdStrike & Welltower (Zacks)
07:00AM	United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences (Business Wire)
Aug-24-26 09:59AM	United Therapeutics Ralinepag NDA Accepted by FDA With June 2027 Decision Date (InvestorsHub)
07:30AM	FDA extends review of Capricor cell therapy; Pain drug startup to go public (BioPharma Dive)
07:00AM	United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension (Business Wire)
08:58PM	Loading…
Aug-12-26 08:58PM	BETA Technologies, Inc. Q2 2026 Earnings Call Summary (Moby)
07:02PM	BETA Technologies Inc (BETA) (Q2 2026) Earnings Call Highlights: Revenue Surges 146% as ... (GuruFocus.com)
Aug-07-26 11:39AM	What Insmed Stock's Premium Is Actually Buying (Trefis)
Aug-05-26 06:13PM	United Therapeutics Corporation Q2 2026 Earnings Call Summary (Moby)
05:01PM	United Therapeutics Corp (UTHR) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress ... (GuruFocus.com)
06:38AM	United Therapeutics: Q2 Earnings Snapshot (Associated Press)
Jul-29-26 06:30AM	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet (Business Wire)
05:30AM	AI Boom Spurs Insider Selling by Nvidia, CoreWeave Billionaires (Bloomberg)
Jul-02-26 06:30AM	United Therapeutics Corporation Acquires Thymmune Therapeutics (Business Wire)
Jul-01-26 07:29AM	BridgeBio gets funding for drug launch; United buys into cell therapy (BioPharma Dive)
Jun-29-26 06:30AM	United Therapeutics Corporation Announces FDA Approval of the LungFX Device for Centralized Ex Vivo Lung Perfusion (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-27-26 07:00AM	United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-18-26 04:15PM	United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026 (Business Wire)
May-17-26 02:15PM	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 (Business Wire)
May-15-26 06:00PM	United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial (Business Wire)
May-12-26 07:00AM	United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-11-26 06:30AM	United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026 (Business Wire)
May-07-26 09:45AM	Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls (The Fly)
May-06-26 08:30PM	MannKind Corporation Q1 2026 Earnings Call Summary (Moby)
04:58PM	United Therapeutics Corporation Q1 2026 Earnings Call Summary (Moby)
06:34AM	United Therapeutics: Q1 Earnings Snapshot (Associated Press)
06:30AM	United Therapeutics Corporation Reports First Quarter 2026 Financial Results (Business Wire)
Apr-29-26 07:00AM	United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors (Business Wire)
Apr-22-26 07:00AM	United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026 (Business Wire)
Apr-20-26 06:30AM	United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026 (Business Wire)
Apr-10-26 09:37AM	Nike downgraded, IBM initiated: Wall Street's top analyst calls (The Fly)
Apr-08-26 07:00AM	United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP for Treatment of Acute Liver Failure (Business Wire)
Mar-30-26 02:21PM	United Therapeutics Stock Soars on Strong Phase 3 Lung Disease Results (GuruFocus.com) +12.53%
11:39AM	United Therapeutics shares surge after positive IPF trial results (Proactive)
11:17AM	United Therapeutics Rises on Positive Study for Cornerstone Drug. Why Shares Could Run Even Higher. (Barrons.com)
11:00AM	United rises on IPF data; Biogen scores positive lupus data and an approval (BioPharma Dive)
08:37AM	Century Aluminum shares surge after Iran strikes threaten supplies - and more stocks on the move (MarketWatch)
07:00AM	United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 (Business Wire)
Mar-11-26 06:14PM	United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine (Business Wire)
Mar-10-26 06:09AM	United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks)
Mar-09-26 12:49PM	Crude Falls Below $100 As Trump Mulls Emergency Reserve Release: What's Moving Markets Monday? (Benzinga) +10.67%
07:00AM	United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program (Business Wire)
Mar-04-26 01:35PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
Mar-03-26 07:00AM	United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference (Business Wire)
Mar-02-26 10:32AM	United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening (Benzinga)
06:30AM	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy (Business Wire)
Mar-01-26 10:04AM	H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600 (Insider Monkey)
Feb-27-26 05:29AM	Zoetis Stock: Is ZTS Underperforming the Healthcare Sector? (Barchart)
Feb-26-26 05:03PM	MannKind Q4 Earnings Call Highlights (MarketBeat) -5.89%
04:02PM	Stocks Showing Market Leadership: United Therapeutics Earns 91 RS Rating (Investor's Business Daily)
12:25PM	Why United Therapeutics (UTHR) Shares Are Sliding Today (StockStory)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
07:42AM	Stock Market News for Feb 26, 2026 (Zacks)
04:32AM	United Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-25-26 04:33PM	United Therapeutics Corporation Q4 2025 Earnings Call Summary (Moby) +13.03%
04:02PM	United Therapeutics Corp (UTHR) Q4 2025 Earnings Call Highlights: Record Revenue and Promising ... (GuruFocus.com)
12:30PM	Compared to Estimates, United Therapeutics (UTHR) Q4 Earnings: A Look at Key Metrics (Zacks)
12:15PM	United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates (Zacks)
06:47AM	United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates (StockStory)
06:45AM	United Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-23-26 10:22PM	United Therapeutics (UTHR) Q4 Earnings Report Preview: What To Look For (StockStory)
11:40AM	USNA or UTHR: Which Is the Better Value Stock Right Now? (Zacks)
07:00AM	United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-20-26 09:15AM	Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-17-26 05:25PM	USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-11-26 07:00AM	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026 (Business Wire)
Feb-06-26 11:04AM	Merck's Subdued 2026 Outlook: What it Means After Q4 Results? (Zacks)
Jan-29-26 10:32PM	A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack (StockStory)
Jan-28-26 10:15AM	Merck's Non-Oncology Drugs Q4 Performance: What to Expect (Zacks)
Jan-27-26 10:33PM	Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) (StockStory)
Jan-26-26 08:55AM	United Therapeutics Reports Early Success For External Liver Support In Acute Failure (Benzinga)
07:00AM	United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP in Patients with Acute Liver Failure (Business Wire)
Jan-22-26 07:00AM	United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 19 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 20 04:36 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 19 '26	Sale	543.32	9,500	5,161,576	324,443	Oct 20 04:36 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 16 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 19 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 16 '26	Sale	534.66	9,500	5,079,275	324,443	Oct 19 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 15 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 16 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 15 '26	Sale	546.65	9,500	5,193,200	324,443	Oct 16 04:35 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 15 '26	Option Exercise	146.03	8,300	1,212,049	53,472	Oct 16 04:34 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 15 '26	Sale	544.30	8,300	4,517,709	45,172	Oct 16 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 14 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 15 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 14 '26	Sale	539.99	9,500	5,129,873	324,443	Oct 15 04:34 PM
PAUL MAHON	Officer	Oct 15 '26	Proposed Sale	544.30	8,300	4,517,709		Oct 15 04:22 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 13 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 14 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 13 '26	Sale	545.52	9,500	5,182,414	324,443	Oct 14 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 12 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 13 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 12 '26	Sale	550.70	9,500	5,231,666	324,443	Oct 13 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 09 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 13 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 09 '26	Sale	544.94	9,500	5,176,936	324,443	Oct 13 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 08 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 09 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 08 '26	Sale	534.31	9,500	5,075,919	324,443	Oct 09 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 07 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 08 05:28 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 07 '26	Sale	548.95	9,500	5,215,015	324,443	Oct 08 05:28 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 06 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 07 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 06 '26	Sale	538.67	9,500	5,117,412	324,443	Oct 07 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 05 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 06 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 05 '26	Sale	541.64	9,500	5,145,537	324,443	Oct 06 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 02 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 05 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 02 '26	Sale	549.37	9,500	5,219,015	324,443	Oct 05 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 01 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 02 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 01 '26	Sale	576.47	9,500	5,476,462	324,443	Oct 02 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 01 '26	Option Exercise	146.03	8,300	1,212,049	53,472	Oct 01 05:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 01 '26	Sale	564.95	8,300	4,689,051	45,172	Oct 01 05:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 30 '26	Sale	550.22	1,920	1,056,425	324,443	Oct 01 05:22 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 30 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Oct 01 05:20 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 30 '26	Sale	517.97	7,580	3,926,177	326,363	Oct 01 05:20 PM
MARTINE ROTHBLATT	Director	Oct 01 '26	Proposed Sale	541.89	209,000	113,255,010		Oct 01 04:37 PM
PAUL MAHON	Officer	Oct 01 '26	Proposed Sale	564.95	8,300	4,689,051		Oct 01 04:07 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 29 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 30 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 29 '26	Sale	477.42	9,500	4,535,480	324,443	Sep 30 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 28 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 29 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 28 '26	Sale	480.85	9,500	4,568,106	324,443	Sep 29 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 25 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 28 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 25 '26	Sale	476.17	9,500	4,523,635	324,443	Sep 28 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 24 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 25 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 24 '26	Sale	473.55	9,500	4,498,753	324,443	Sep 25 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 23 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 24 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 23 '26	Sale	491.57	9,500	4,669,918	324,443	Sep 24 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 22 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 23 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 22 '26	Sale	494.83	9,500	4,700,851	324,443	Sep 23 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 21 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 22 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 21 '26	Sale	494.55	9,500	4,698,271	324,443	Sep 22 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 18 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 21 04:44 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 18 '26	Sale	494.79	9,500	4,700,505	324,443	Sep 21 04:44 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 17 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 18 04:41 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 17 '26	Sale	496.06	9,500	4,712,580	324,443	Sep 18 04:41 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 17 '26	Option Exercise	146.03	8,300	1,212,049	53,472	Sep 18 04:40 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 17 '26	Sale	497.54	8,300	4,129,608	45,172	Sep 18 04:40 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 16 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 17 04:43 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 16 '26	Sale	501.39	9,500	4,763,172	324,443	Sep 17 04:43 PM
PAUL MAHON	Officer	Sep 17 '26	Proposed Sale	497.54	8,300	4,129,608		Sep 17 04:19 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 15 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 16 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 15 '26	Sale	501.59	9,500	4,765,119	324,443	Sep 16 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 14 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 15 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 14 '26	Sale	504.12	9,500	4,789,152	324,443	Sep 15 04:34 PM
Mesa Nilda	Director	Sep 14 '26	Option Exercise	110.86	130	14,412	6,560	Sep 15 04:33 PM
Mesa Nilda	Director	Sep 14 '26	Sale	505.87	228	115,338	5,580	Sep 15 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 11 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 14 04:43 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 11 '26	Sale	500.82	9,500	4,757,773	324,443	Sep 14 04:43 PM
NILDA MESA	Director	Sep 14 '26	Proposed Sale	505.87	228	115,338		Sep 14 04:40 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 10 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 11 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 10 '26	Sale	502.35	9,500	4,772,295	324,443	Sep 11 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 09 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 10 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 09 '26	Sale	501.84	9,500	4,767,467	324,443	Sep 10 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 08 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 09 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 08 '26	Sale	499.03	9,500	4,740,795	324,443	Sep 09 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 04 '26	Option Exercise	117.76	9,500	1,118,720	333,943	Sep 08 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 04 '26	Sale	489.20	9,500	4,647,354	324,443	Sep 08 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 03 '26	Option Exercise	134.32	9,500	1,276,071	333,943	Sep 04 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 03 '26	Sale	487.54	9,500	4,631,619	324,443	Sep 04 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 03 '26	Option Exercise	146.03	8,300	1,212,049	53,472	Sep 03 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 03 '26	Sale	482.03	8,300	4,000,836	45,172	Sep 03 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 02 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Sep 03 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 02 '26	Sale	493.46	9,500	4,687,841	324,443	Sep 03 04:31 PM
PAUL MAHON	Officer	Sep 03 '26	Proposed Sale	482.03	8,300	4,000,837		Sep 03 04:01 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 01 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Sep 02 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 01 '26	Sale	514.09	9,500	4,883,839	324,443	Sep 02 04:34 PM
MARTINE ROTHBLATT	Officer	Sep 01 '26	Proposed Sale	510.38	199,500	101,820,810		Sep 01 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 31 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Sep 01 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 31 '26	Sale	511.09	9,500	4,855,312	324,443	Sep 01 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 28 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Aug 31 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 28 '26	Sale	517.51	9,500	4,916,363	324,443	Aug 31 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 27 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Aug 28 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 27 '26	Sale	522.57	9,500	4,964,376	324,443	Aug 28 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 26 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Aug 27 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 26 '26	Sale	517.28	9,500	4,914,190	324,443	Aug 27 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 25 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Aug 26 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 25 '26	Sale	517.71	9,500	4,918,273	324,443	Aug 26 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 24 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Aug 25 04:38 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 24 '26	Sale	511.97	9,500	4,863,730	324,443	Aug 25 04:38 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 21 '26	Option Exercise	135.42	9,500	1,286,490	333,943	Aug 24 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 21 '26	Sale	518.39	9,500	4,924,666	324,443	Aug 24 04:30 PM

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

M.B.A.Dr. Martine A. Rothblatt J.D.

President & COOMr. Michael I. Benkowitz

CFO & TreasurerMr. James C. Edgemond

Executive VPMr. Paul A. Mahon J.D.

Manager of Investor RelationsHarrison Silvers

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UTHR

United Therapeutics Corp

Upgrade your Finviz experience